US-Based Plasmid Manufacturing Simplify Your Supply Chain
Manufacturing Excellence for Next-generation Therapeutics
The World’s Largest Capacity for Plasmid DNA Manufacturing
VGXI is a leading-edge CDMO dedicated to revolutionizing the biopharmaceutical industry with best-in-class nucleic acid-based products and services. We deliver manufacturing excellence in state-of-the-art facilities with the agility and scale to meet projects of all sizes to serve the global community of next-generation therapeutic developers.
Pre-clinical Plasmids
HD Plasmids
cGMP Plasmids
Manufacturing Services
Pre-clinical Plasmids
VGXI’s Pre-clinical Plasmid Production Service provides high purity plasmid preparations for early research, in vivo animal studies, and preclinical assessments for advanced therapies.
Learn MoreHD Plasmids
VGXI’s Highly Documented (HD) Plasmid Production Service provides high supercoil, low endotoxin plasmids for use as an ancillary raw material in cGMP manufacturing and IND enabling studies.
Learn MorecGMP Plasmids
VGXI’s cGMP Plasmid Production Service produces injectable-grade plasmid DNA for human clinical trials, diagnostic reagents, and the GMP production of cell and gene therapies.
Learn MoreManufacturing Services
Our end-to-end solutions include Process Development & Optimization, Tech Transfer Support, GMP Cell Banking & Testing, Bulk Stability Testing, Fill/Finish Services, Product Stability Testing, Rapid TAT Manufacturing, and RNA Production.
Learn More
Applications
Plasmid DNA plays a critical role in the development and production of next-generation therapeutic modalities including gene therapies, personalized cell therapies, mRNA-based therapeutics, and DNA vaccines. These applications all rely on plasmid DNA, which can be genetically engineered to encode viral vector elements, CRISPR/Cas9 components, and other sequences, for delivery into target cells. Our proven expertise in plasmid production has been instrumental in propelling these advanced therapeutics forward. We are dedicated to supporting our clients now and into the future to bring innovative treatments to market to help patients in need worldwide.
Gene Therapy
Gene therapy is a cutting-edge approach that aims to treat or cure diseases by replacing or inactivating disease-causing genes or introducing new or modified genes to treat or cure diseases.
Learn MoreCell Therapy
Gene-modified cell therapy or ex vivo gene therapy involves genetically modification of cells outside the body before infusion into the patient to combat diseases, such as in Chimeric antigen receptor T-cell (CAR T-cell) therapy used for treating certain hematologic cancers.
Learn MoreImmunotherapy & Vaccines
Immunotherapy and nucleic acid vaccines prevent and/or treat diseases by enhancing the immune system's ability to launch potent immune responses to target pathogens and cancer cells.
Learn More
Capabilities
With a strong customer-centric approach, VGXI brings two decades of expertise delivering exceptional products and services to the global market. Our capabilities are diverse, encompassing plasmid manufacturing in our state-of-the-art facilities, analytical testing, tech transfer, process development, quality management, and comprehensive regulatory expertise. We prioritize customer satisfaction and firmly believe that when our clients succeed, we succeed.
Read Our Latest Blog Post
Check out the VGXI blog where we examine scientific trends, innovation, technological advancements in plasmid DNA manufacturing, and uncover how next-generation therapeutics are shaping the future of medicine and improving patients’ lives.
